01. Letter from the President

Dear Friends,

I hope you had a good start of the year. I wish you and your family all the best for 2019!

2018 was another busy year for the European Cystic Fibrosis Society, with not only the Basic Science Conference in Greece and the Annual conference in Belgrade, but a number of special projects and Working Group meetings were held and some selected updates are given below. I would just like to highlight that, thanks to Daniel Peckham who leads the Education project with the help of Helen Chadwick as coordinator, the ECFS Education platform was launched last December. Please follow the instructions on the education homepage (https://www.ecfs.eu/education) and discover a selection of courses and webcasts from the Seville and Belgrade ECFS conferences, and a library of educational resources. Each month, you will also find a selection of courses on a specific topic: “new therapies” were the topic of January, and this month, you will learn everything about “lung microbiology”. Read more about it below!
There will be ECFS Board elections in 2019 as Margarida Amaral and Isabelle Sermet-Gaudelus will finish their terms in June. I would like to encourage you all to consider your own nomination or to nominate an ECFS member you believe would benefit the ECFS community by being actively engaged in the Board. Please consider how important these elections are for the future of the Society. Further information about the elections is included later in the Newsletter.

Planning for the 2019 Conference is well underway with all necessary information available on the website. I would like to thank all those who have submitted abstracts and all the speakers who have accepted to contribute to the conference. For the second year, there is a special discounted rate for attendees from lower income countries in an effort to encourage participation of healthcare professionals from all countries. We have excellent programmes and courses planned and we look forward to your participation.

We have a lot to do over the coming months and I hope you will join us for some of these activities.

Many thanks, as always, to Dr. Henry Ryley for compiling the current references in cystic fibrosis contained in this Newsletter

Please contact us if you have news items you would like to have included in future Newsletters or published on our website.

Yours sincerely,

Isabelle Fajac, ECFS President
02. Upcoming Events

- ECFS Diagnostic Network Working Group Meeting - 14-16 February 2019, Tunis, Tunisia
- 13th European Young Investigators Meeting - 27 February - 01 March 2019, Paris, France
- 16th ECFS Basic Science Conference - 27-30 March 2019, Dubrovnik, Croatia
- ECFS REAP Meeting - 29-30 March 2019, Postdam, Germany
- ECFS Board Elections - Polls will open 15 May 2019
- ECFS Board Meeting - 04 June 2019, Liverpool, United Kingdom
- 42nd European CF Conference - 05-08 June 2019, Liverpool, United Kingdom

03. Deadlines

- Nomination ECFS Award 22 February 2019
- Nomination Gerd Döring Award 22 February 2019
- Nomination ECFS Board Election 15 March 2019
- Application Journal of Cystic Fibrosis Editor-in-Chief 31 March 2019

04. ECFS Award - Call for nominations

The ECFS Award is given annually to honour a person who has made an outstanding contribution to our basic understanding of cystic fibrosis or to the treatment or care of patients with cystic fibrosis. The winner of the award will be invited to present a lecture at the Opening Plenary on 5 June 2019 of the annual conference in Liverpool.

You are cordially invited to nominate a candidate for this award. The deadline for proposals is 22 February, 2019. Please mail your proposal, accompanied by a detailed motivation and curriculum vitae of the candidate to the ECFS Executive Director Christine Dubois (christine.dubois@ecfs.eu).

05. Gerd Döring Award - Call for nominations

The Gerd Döring Award is an initiative of the European Cystic Fibrosis Society and is given annually to honour an exceptional young European scientist in their early career. The Award, a monetary donation of 5,000 euro to support research, will be presented at the Opening Plenary of the annual ECFS conference in Liverpool.

The award will be judged primarily on a paper published in the previous 3 calendar years (2016-2018) which has made a significant impact on the understanding or treatment of Cystic Fibrosis. Personal statements and CVs will make a 20% contribution to the scoring.
The award is open to PhD students and post-doctoral researchers with up to a maximum of four years’ academic research experience following the completion of their PhD, or be of equivalent professional standing at the date of publication of the paper.

We encourage mentors, supervisors and co-workers of today’s most exceptional early career European scientists to send in nominations for this competition. The deadline for proposals is **22 February, 2019**. Please mail your proposal, accompanied by a detailed personal statement, a PDF of the nominated paper and curriculum vitae of the candidate to the ECFS Executive Director Christine Dubois (christine.dubois@ecfs.eu)

06. ECFS Board Elections - Call for nominations

The ECFS cordially invites nominations for 2 Board positions.

Margarida Amaral is ending her second term and Isabelle Sermet-Gaudelus will finish her first term on the Board in 2019.

Job Descriptions and person specifics are available for Board members. [Board Member’s Job Description](#).

Nominations should be sent to the ECFS Executive Director Christine Dubois (christine.dubois@ecfs.eu) by **15 March 2019** together with a personal statement, confirmation that the candidate has agreed to the nomination, and a curriculum vitae. All nominated candidates must be current members of the ECFS. Information about the nominated candidates will be sent to the membership in April for an online vote prior to the Annual General Meeting in June where the results will be announced.

07. Editor-in-Chief of the Journal of Cystic Fibrosis (JCF)

The European Cystic Fibrosis Society (ECFS) is looking to appoint the next Editor-in-Chief of the Journal of Cystic Fibrosis (JCF).

The current Editor-in-Chief, Scott Bell, will complete his mandate on June 30, 2020. It is anticipated that the next Editor-in-Chief will work very closely with the incumbent from July 2019, assuming full responsibility in July 2020. The ECFS is seeking candidates with the following qualities for this challenging position: previous international editorial experience, organisational ability, leadership skills, prestige in the field, willingness to devote time to the JCF and ECFS, and the ability to communicate clearly.

A more detailed job description for the role of the JCF Editor-in-Chief can be found [here](#).

To apply, please send a CV and a covering letter of suitability for the post to the ECFS office info@ecfs.eu by the deadline 31 March 2019. Interviews of selected candidates will be held in June during the 42nd European Cystic Fibrosis conference.
08. ECFS Education - New feature on the platform!

The ECFS Education launched a new feature on the Education Platform. Each month we will be posting a ‘Highlight of the month’ which will include relevant talks and material on a particular topic.

In case you missed it, the topic for January 2019 was ‘New Therapies’, and brought together talks from the ECFS conferences in Belgrade (2018) and Seville (2017), and a presentation from ‘The Treatment of Adults with CF’ course. They are still available on the platform!

The topic for February 2019 is ‘lung microbiology’ and brings together symposiums from the ECFS conferences in Belgrade (2018) and Seville (2017), two talks from ‘The Treatment of Adults with CF’ course, and a presentation (available in English and Spanish) from ‘The Essential Toolkit’ course.

Join us on the Education Platform [here](#).

09. Welcome to Emily!

A few weeks ago, Emily Bateman joined the ECFS Executive team as Administrative and Events coordinator.

Emily is a trained speech and language therapist. When working at the NHS, she was involved in the design, delivery and organisation of formal training packages for staff working within schools and has some experience with event organisation.

She will mainly focus on the membership and the organisation of the conferences. Emily is an enthusiastic person and we are happy that she will strengthen the team.

10. ECFS Meetings - CTN, Patient Registry, Standards of Care

ECFS Registry Steering Committee

The ECFS Clinical Trials Network, the ECFS Patient Registry Steering Committees met on 24-25 January in Brussels for their annual winter meetings. The Standards of Care Group also met in
This was an excellent opportunity to meet across ECFS projects, discuss common subjects and find new and even better opportunities for cooperation.

11. 16th European Basic Science Conference

The 2019 ECFS Basic Science Conference will take place in Dubrovnik, Croatia, from 27 to 30 March 2019.
We are delighted that Prof. Isabelle Callebaut (FR) has accepted to be the conference chairperson, supported by Prof. Carlos Farinha (PT) and Dr. Martin Mense (US).
We have an exciting programme this year again and we look forward to fruitful discussions of data and ideas in an informal and interactive environment. Learn more here.

12. ECFS REAP Meeting 29-30 March 2019

We are happy to announce the ECFS regional educational activities platform (ECFS-REAP) meeting, which will be held 29 and 30 March in Postdam, Germany. This meeting will be of special interest to physicians and scientists who are/or want to be involved in gastrointestinal or/and otorhinological issues in cystic fibrosis. The programme details can be found here. Unfortunately, there is limited seating and an application is to be sent to the organisers before registration. The application form can be found here and is to be sent to the coordinator of the meeting, Katja Erler, katja.erler@med.uni-jena.de

13. 42nd European CF Conference - Liverpool, United Kingdom
The Annual Conference is fast approaching. We had a record number of abstract submissions (close to 700!) and we are sure we will have a record attendance in Liverpool. To ease the access for all, we have a limited number of single day registration available and hope it will answer the flexibility needs of the delegates. We have also introduced a Team ticket, allowing 3 allied health professionals from the same team to share a registration, more information on the Team ticket here. Last year we introduced a reduced registration rate for participants working in countries classified as low-income economies, lower-middle-income economies and upper-middle-income economies by the World Bank. We hope this opportunity will encourage many more healthcare professionals to attend the conference. All information concerning the registration to the conference can be found here. And do not forget to have a look at the scientific programme here.

14. New course! Acceptance and Commitment Therapy for CF care

Tuesday 4 June 2019 - All day

Acceptance & Commitment Therapy (ACT) is an evidence-based “3rd wave” therapy that aims to help people live fulfilling lives even in the presence of difficult experiences, and the powerful thoughts and feelings that they will inevitably bring. This short course will introduce the use of ACT in supporting people with serious physical health problems, with specific reference to cystic fibrosis. Through teaching, experiential exercises and role-play, participants will learn how people can become more Aware, Open and Engaged, and use these skills to live more fulfilling lives in the presence of serious physical difficulties. Although the course assumes no prior knowledge of the ACT model, it is only open to psychosocial professionals active in CF care, and who have some experience/knowledge of psychological therapy and active listening/counselling.

Registration information

15. New course! Nutrition advanced course - scrutinizing the future for nutrition in cystic fibrosis

(Limited Seating) Tuesday 4 June - Half Day

This nutrition advanced course will be looking at the latest and future developments in nutrition aspects in cystic fibrosis. Emerging topics and the data that underpin them will be critically presented and explored, leaving room for interaction and discussions. Participants will be presented with an overview of possible challenges and changes facing nutritional management in the future. This course is meant for experienced health care nutrition providers including advanced dietitians, GI leads and all CF team members

Registration information

16. Physiotherapy short course - Exercise testing in CF - who, when and why

Tuesday 4 June & Wednesday 5 June 2019 - One and a half days

The course is suitable for those new to exercise testing, by providing attendees with an understanding of exercise physiology as well as an overview of available tests, before focusing on the utility of cardiopulmonary exercise testing (CPET) in CF. The course is also applicable to those with experience of exercise testing, and will help build on existing knowledge with sessions dedicated to interpreting and reporting CPET data; as well as how CPET results can be translated into individualised exercise training plans for people with CF. The course will include both theory and practical exercise testing sessions, whilst small group sessions allow lots of opportunity for discussion between participants and course tutors.

Registration information
17. An introductory course in Cognitive Behavioural Therapy and Interpersonal Therapy

Wednesday 05 June 2019 - All day

The course is intended for any member of the CF multidisciplinary team who wants to be introduced to, or updated about, Cognitive Behavioural Therapy (CBT) and Interpersonal Therapy (IPT) with the aim of improving mental health care for patients with cystic fibrosis and their families. This one-day course consists of a basic introduction in CBT and IPT. The course will highlight the principles of assessment and a variety of intervention techniques. CBT and IPT have been applied in medical settings for decades and the course will include examples of CBT and IPT approaches in CF.

Registration information

18. Current references in CF

Please scroll to next page for full list

Smith S., Rowbotham NJ., Charbek E. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis *Cochrane Database of Systematic Reviews* 2018; : 10:CD008319

Spero MA., Newman DK. Chlorate Specifically Targets Oxidant-Starved, Antibiotic-Tolerant Populations of Pseudomonas aeruginosa Biofilms *mBio* 2018; 9: 5:e01400-18


Wright MFA., Bush A., Carr SB. Hypersensitivity reactions to intravenous antibiotics in cystic fibrosis *Paediatric Respiratory Reviews* 2018; 27: 9 - 12


Zettner EM., Geser MA. Progressive Hearing Loss among Patients with Cystic Fibrosis and Parenteral Aminoglycoside Treatment *Otolaryngology-Head and Neck Surgery* 2018; 159: 887 - 894


Cardiology

Bakhshayeshkaram M., Aghahasemi F., Vaezi F., Kakhooee S., Salehi Y., Hassanzad M., Jamaati HR., Velayati AA. CT-measured pulmonary artery diameter as an independent predictor of pulmonary hypertension in cystic fibrosis *Polish Journal of Radiology* 2018; 83:

Causer AJ., Shute JK., Cummings MH., Shepherd AL., Bright V., Connett G., Allenby MI., Carroll MP., Daniels T., Saynor ZL. Cardiopulmonary exercise testing with supramaximal verification produces a safe and valid assessment of $\dot{V}O_2$max in people with cystic fibrosis: a retrospective analysis *Journal of Applied Physiology* 2018; 125: 1277 - 1283

Eising JB., van der Ent CK., Teske AJ., Vanderschuren MM., Uiterwaal CSPM., Meijboom FJ. Young patients with cystic fibrosis demonstrate subtle alterations of the cardiovascular system *Journal of Cystic Fibrosis* 2018; 17: 643 - 649


Cell Biology


Balazs A., Mall MA. Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis *Frontiers in Pharmacology* 2018; 9: ArNo: 1112

Bebok Z., Fu JW. Stressors and Stress Responses in Cystic Fibrosis *Endoplasmic Reticulum Stress in Diseases* 2018; 5: 11 - 29

Bouvet GF., Voisin G., Cyr Y., Bascunana V., Masse C., Berthaume Y. DNA Methylation Regulates RGS2-induced S100A12 Expression in Airways Epithelial Cells *American Journal of Respiratory and Cell Molecular Biology* 2018; 59: 601 - 613

Canato S., Santos JD., Carvalhal AS., Aloría K., Amaral MD., Matthiesen R., Falcao AO., Farinha CM. Proteomic interaction profiling reveals KIFC1 as a factor involved in early targeting of F508del-CFTR to degradation *Cellular and Molecular Life Sciences* 2018; 75: 4495 - 4509

Castellani S., Di Gioia S., di Toma L., Conese M. Human Cellular Models for the Investigation of Lung Inflammation and Mucus Production in Cystic Fibrosis *Analytical Cellular Pathology* 2018; ArNo: 3839803

Chen QW., Pandi SPS., Kerrigan L., McElvaney NG., Greene CM., Elborn JS., Taggart CC., Weldon S. Cystic fibrosis epithelial cells are primed for apoptosis as a result of increased Fas (CD95) *Journal of Cystic Fibrosis* 2018; 17: 616 - 623


Delpiano L., Thomas JJ., Yates AR., Rice SJ., Gray MA., Saint-Criq V. Esomeprazole Increases Airway Surface Liquid pH in Primary Cystic Fibrosis Epithelial Cells *Frontiers in Pharmacology* 2018; 9: ArNo: 1462


Imberti R., Garavaglia ML., Verduci L., Cannavale G., Balduzzi G., Papetti S., Mazzanti M. Antiestrogen- and tamoxifen-induced effects on calcium-activated chloride currents in epithelial cells carrying the Delta F508-CFTR point mutation *Respiratory Research* 2018; 19: ArNo: 198


Lopes-Pacheco M., Kitoko JZ., Morales MM., Pets-Silva H., Rocco PRM. Self-complementary and tyrosine-mutant rAAV vectors enhance transduction in cystic fibrosis bronchial epithelial cells *Experimental Cell Research* 2018; 372: 99 - 107

Perra L., Balloy V., Foussigniere T., Moissenet D., Petat H., Mungrue IN., Touqui L., Corvol H., Chignard M., Guillot L. CHAC1 Is Differentially Expressed in Normal and Cystic Fibrosis Bronchial Epithelial Cells and Regulates the Inflammatory Response Induced by Pseudomonas aeruginosa *Frontiers in Immunology* 2018; 9: ArNo: 2823

Clinical

Armiento R., Ranganathan SC., Harrison J.
The implementation of a cystic fibrosis annual review process in a tertiary paediatric hospital
Archives of Disease in Childhood-Education and Practice Edition 2018; 103: 241 - 243

Breuer O., Caudri D., Stick S., Turkovic L.
Predicting disease progression in cystic fibrosis
Expert Review of Respiratory Medicine 2018; 12: 905 - 917

Age-related heterogeneity in dental caries and associated risk factors in individuals with cystic fibrosis ages 6-20 years: A pilot study
Journal of Cystic Fibrosis 2018; 17: 747 - 759

Corriveau S., Sykes J., Stephenson AL.
Cystic fibrosis survival: the changing epidemiology
Current Opinion in Pulmonary Medicine 2018; 24: 574 - 578

de Winter-De Groot KM., Jennings HM., van Uum RT., Dekkers JF., Berkers G., Vonk A., Kruijshoek E., Oppelaar H., Vries R., Clevers H., Berkers G., Vonk A., Kruisselbrink E., Oppelaar H., Vries de Winter
Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function
European Respiratory Journal 2018; 52: 3-1702529

Decheche MC., Tamanini A., Cabrini G.
Molecular basis of cystic fibrosis: from bench to bedside
Annals of Translational Medicine 2018; 6: 17:334
dos Santos ALM., Santos HD., Nogueira MB., Tavora HTO., da Cunha MDJP., Seixas RBPD., Monte LDV., de Carvalho E.
Cystic Fibrosis: Clinical Phenotypes in Children and Adolescents

Edwards TC., Emerson J., Genatossi A., McNamara S., Goss C., Patrick DL., Onchiri F., Rosenfeld M.
Initial development and pilot testing of observer-reported outcomes (ObsROs) for children with cystic fibrosis ages 0-11 years
Journal of Cystic Fibrosis 2018; 17: 680 - 686

Guo XB., Liu KQ., Liu YP., Situ YS., Tian XL., Xu KF., Zhang X.
Clinical and genetic characteristics of cystic fibrosis in CHINESE patients: a systemic review of reported cases
Orphanet Journal of Rare Diseases 2018; 13: ArNo: 224

 Hoch H., Sontag MK., Scarbro S., Juarez-Colunga E., McLean C., Kempe A., Sagel SD.
Clinical outcomes in US infants with cystic fibrosis from 2001 to 2012
Pediatric Pulmonology 2018; 53: 1492 - 1497

Jessula S., Van den Hof M., Mateos-Corral D., Mills J., Davies D., Romao RLP.
Predictors for surgical intervention and surgical outcomes in neonates with cystic fibrosis
Journal of Pediatric Surgery 2018; 53: 2150 - 2154

Kern-Goldberger AS., Hessels AJ., Salman L., Quittell LM.
Understanding of safety monitoring in clinical trials by individuals with CF or their parents: A qualitative analysis
Journal of Cystic Fibrosis 2018; 17: 736 - 741

Rho J., Ahn C., Gao A., Sawicki GS., Keller A., Jain R.
Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States A National and Regional Cohort Study
American Journal of Respiratory and Critical Care Medicine 2018; 198: 1055 - 1063

Ruffles TJC., Black R., Nicholls W., Laing B., Isles A.
Osteogenic Sarcoma in an Adolescent With Cystic Fibrosis: Successful Treatment Despite Significant Obstacles
Frontiers in Pediatrics 2018; 6: ArNo: 245

Saavedra MT., Quon BS., Faino A., Caceres SM., Poch KR., Sanders LA., Malcolm KC., Nichols DP., Sagel SD., Taylor-Cousar JL., Leach SM., Strand M., Nick JA.
Whole Blood Gene Expression Profiling Highlights Severe Morbidity and Mortality in Cystic Fibrosis: A 5-Year Follow-Up Study

Clinical expression of cystic fibrosis in a large cohort of Italian siblings
BMC Pulmonary Medicine 2018; 18: ArNo: 196

Trigo-Salado C., Leo-Carnerero E., de-la-Cruz-Ramírez D.
Cronh's disease and cystic fibrosis: there is still a lot to learn
Revisa Española de Enfermedades Digestivas 2018; 110: 836

Wood ME., Stockwell RE., Bell SC.
Use of Masks in Patients with Cystic Fibrosis Reply
American Journal of Respiratory and Critical Care Medicine 2018; 198: 1589 - 1590

Zuckerman JB., Saiman L.
Use of Masks in Patients with Cystic Fibrosis
American Journal of Respiratory and Critical Care Medicine 2018; 198: 1588 - 1589

Databases & Registries

Desal S., Wong H., Sykes J., Stephenson AL., Singer J., Quon BS.
Clinical Characteristics and Predictors of Reduced Survival for Adult-diagnosed Cystic Fibrosis Analysis of the Canadian CF Registry

Keogh RH., Seaman SR., Barrett JK., Taylor-Robinson D., Szczesniak R.
Dynamic Prediction of Survival in Cystic Fibrosis A Landmarking Analysis Using UK Patient Registry Data
Epidemiology 2019; 30: 29 - 37
Diabetes

Banavath LN., Kumar R., Dayal D., Yadav J., Sachdeva N., Mathew JL., Vaidya PC., Singh M.
Glucose intolerance in children with cystic fibrosis: a developing country's perspective
Journal of Pediatric Endocrinology & Metabolism 2018; 31; 1139 - 1146

Bechtold SM., Rohrer TR., Raile K., Hofer S., Thon A., Boettcher C., Konrad K., Pozza RD., Bollow E., Holl RW.
Diabetes mellitus in pediatric solid organ recipients without and with cystic fibrosis: An analysis from the German-Austrian diabetes database (Diabetes Patienten Verlaufsdoekumentation)
Pediatric Diabetes 2018; 19; 1191 - 1197

Birch L., Lithander FE., Hewer SL., Harriman K., Hamilton-Shield J., Perry R.
Dietary interventions for managing glucose abnormalities in cystic fibrosis: a systematic review protocol
Systematic Reviews 2018; 7: ArNo: 98

Brugha R., Wright M., Nolan S., Bridges N., Carr SB.
Quantifying fluctuation in glucose levels to identify early changes in glucose homeostasis in cystic fibrosis
Journal of Cystic Fibrosis 2018; 17: 791 - 797

Chan CL., Vigers T., Pyle L., Zeitler PS., Sagel SD., Nadeau KJ.
Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline
Journal of Cystic Fibrosis 2018; 17: 783 - 790

Colombo C., Alicandro G., Gambuzza S., Mileto P., Mari A., Grespan E., Nazzari E., Russo MC., Battezzati A.
Ventilation inhomogeneity is associated with OGTT-derived insulin secreotory defects in cystic fibrosis
Pediatric Pulmonology 2019; 54: 141 - 149

Frost F., Dyce P., Nazareth D., Malone V., Walshaw MJ.
Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes
Journal of Cystic Fibrosis 2018; 17: 798 - 803

Moran A., Pillay K., Becker D., Granados A., Hameed S., Acerini CL.
ISPAD Clinical Practice Consensus Guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescents
Pediatric Diabetes 2018; 19:

Nyrjsey SC., Sheikh S., Hadjiliadis D., De Leon DD., Peleckis AJ., Eiel JN., Kubrak C., Stefanovski D., Rubenstone RC., Rickels MR., Kelly A.
beta-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose >= 155 mg/dL
Pediatric Diabetes 2018; 19: 1173 - 1182

Diagnosis

Brown KL., Flume PA.
Pediatric and Adult Recommendations Vary for Sibling Testing in Cystic Fibrosis
Journal of Genetic Counseling 2018; 27: 1049 - 1054

Gomez CCS., Marson FAL., Servidioni MF., Ribeiro AF., Ribeiro MAGO., Gama VAL., Costa ET., Ribeiro JD., Vieira FU.
Evaluation of continuous constant current and continuous pulsed current in sweat induction for cystic fibrosis diagnosis
BMC Pulmonary Medicine 2018; 18: ArNo: 153

Gonzalez-Andrade F.
Standardized clinical criteria and sweat test combined as a tool to diagnose Cystic Fibrosis
Heliyon 2018; 4: 12:e01050

Kassal P., Steinberg MD., Horak E., Steinberg IM.
Wireless fluorometer for mobile and low cost chemical sensing: A paper based chloride assay
Sensors and Actuators B-Chemical 2018; 275: 230 - 236

Soft, Skin-Interfaced Microfluidic Systems with Wireless, Battery-Free Electronics for Digital, Real-Time Tracking of Sweat Loss and Electrolyte Composition
Small 2018; 14: 45:1802876

Lemke J., Gartner M., Kemen C., Hoger PH.
Clinical Diagnosis of Mucoviscidosis in false-negative Mucoviscidosis Neonatal Screening
Monatschrift Kinderheilkunde 2018; 166: 889 - 893

Moser C., Thomsen TR., Holby N.
Next generation microbiology and cystic fibrosis diagnostics: are we there yet?
Current Opinion in Pulmonary Medicine 2018; 24: 599 - 605

Qiu LR., Yang FJ., He YH., Yuan HQ., Zhou JH.
Clinical characterization and diagnosis of cystic fibrosis through exome sequencing in Chinese infants with Barter-syndrome-like hypokalemia alkalosis
Frontiers of Medicine 2018; 12: 550 - 558

Wiercke JL., Lo SF.
Advances in the Diagnosis and Management of Cystic Fibrosis in the Genomic Era
Clinical Chemistry 2018; 64: 898 - 908

Epidemiology

Adyan TA., Stepanova AA., Krasovskiy SA., Polyakov AV.
Updating Diagnostic Spectrum of Recurring CFTR Mutations
Russian Journal of Genetics 2018; 54: 1255 - 1244

Spectrum of mutations of cystic fibrosis in the 22 Arab countries: A systematic review
Respirology 2019; 24: 127 - 136

da Rosa KM., de Lima ED., Machado CC., Rispoli T., Silveira VD., Ongaratto R., Comaru T., Pinto LA.
Genetic and phenotypic characteristics of children and adolescents with cystic fibrosis in Southern Brazil
Jornal Brasileiro de Pneumologia 2018; 44: 498 - 504

Characterization of the physical capacity in children of the Chilean National Program of Cystic Fibrosis
Revista Chilena de Pediatría-chil 2018; 89: 638 - 643

Cystic fibrosis: What's new in South Africa in 2019

Exercise

Abdelbasset WK., Soliman GS., Elshehawy A.A., Alrawalli SM.
Exercise capacity and muscle fatigueability alterations following a progressive maximal exercise of lower extremities in children with cystic fibrosis
African Health Sciences 2018; 18: 1236 - 1242
Yang R., Wang X., Zhang W., Li HJ., Wang BB.
Compound heterozygous mutations in CFTR causing CBAVD in
Chinese pedigrees
Molecular Genetics & Genomic Medicine 2018; 6: 1097 - 1103
Yokoyama E., Chavez-Saldana M., Orozco L., Cuevas F., Lezana
JL., Viguera-Villasenor RM., Rojas-Castaneda JC., Landero
DA.
Influence of SNPs in Genes that Modulate Lung Disease Severity in a
Group of Mexican Patients with Cystic Fibrosis
Archives of Medical Research 2018; 49: 18 - 26
Zou WB., Tang XY., Zhou DZ., Qian YY., Hu LH., Yu FF., Yu
D., Wu H., Deng SJ., Liu JH., Zhao AJ., Zhao ZH., Wu HY., Zhu
He L., Masson E., Cooper DN., Perez C., Li ZS.
SPINK1, PRSS1, CTRC, and CFTR Genotypes Influence Disease
Onset and Clinical Outcomes in Chronic Pancreatitis
Clinical and Translational Gastroenterology 2018; 9: ArNo: 204

Growth & Development
Calella P., Valerio G., Brodlie M., Donini LM., Siervo M.
Cystic fibrosis, body composition, and health outcomes: a systematic
review
Nutrition 2018; 55:56: 131 - 139
Paulina BM., Balboa P., Torrejon C., Bozzo R., Boza ML.,
Contreras J., Jorduera P., Astorga L., Weisstaub G.
Bone mineral density, lung function, vitamin D and body composition
in children and adolescents with cystic fibrosis: a multicenter study
Nutrition Hospitaalitas 2018; 35: 789 - 795
Thaker V., Carter B., Putman M.
Recombinant growth hormone therapy for cystic fibrosis in children and young adults
Cochrane Database of Systematic Reviews 2018; : 12:CD008901

Immunology & Inflammation
Bianconi I., Alcala-Franco B., Scarselli M., Dalsass M., Buccato
S., Colaprico A., Marchi S., Masignani V., Baronzi A.
Genome-Based Approach Delivers Vaccine Candidates Against
Pseudomonas aeruginosa
Frontiers in Immunology 2019; 9: ArNo: 3021
Chandler JD., Margaroli C., Horati H., Kilgore MB., Veltman M.,
Liu HK., Taurone AJ., Peng LM., Guglani L., Upal K., Go YM.,
Tiddens HAWM., Scholte BJ., Tiououzian R., Jones DP.,
Janssen HM.
Myeloperoxidase oxidation of methionine associates with early cystic
fibrosis lung disease
European Respiratory Journal 2018; 52: 4:1801118
Chen YDH., Armstrong DA., Salas LA., Hazlett HF., Nymon AB.,
Dessaint JA., Aridgides DS., Mellinger DL., Liu XY., Christensen
BC., Ashare A.
Genome-wide DNA methylation profiling shows a distinct epigenetic
signature associated with lung macrophages in cystic fibrosis
Clinical Epigenetics 2018; 10: ArNo: 152
Coriati A., Masse C., Menard A., Bouvet GF., Berthiaume Y.
Neutrophils as a Potential Source of Chitinae-3-like Protein 1 in
Cystic Fibrosis
Inflammation 2018; 41: 1631 - 1639
da Cunha ALP., da Costa ACC., Vasconcelos Z., Do Carmo
MDT., Chaves CRM.
Fatty acid profile in erythrocytes associated with serum cytokines in
pediatric cystic fibrosis patients
Revista de Nutricao-braziliam Journal of Nutrition 2018; 31: 455 -
466
Elborn JS., Ahuja S., Springman E., Mershon J., Grosswald R.,
Rowe SM.
EMPIRE-CF: A phase II randomized placebo-controlled trial of once-
daily, oral acibimetast in adult patients with cystic fibrosis - Study
design and patient demographics
Contemporary Clinical Trials 2018; 72: 86 - 94

Forrest OA., Ingersoll SA., Preininger MK., Laval J., Limoli DH.,
Brown MR., Lee FE., Bedi B., Sadikot RT., Goldberg JB.,
Tangpricha V., Gagger A., Tiououzian R.
Frontline Science: Pathological conditioning of human neutrophils
recruited to the alwary milieu in cystic fibrosis
Journal of Leukocyte Biology 2018; 104: 665 - 675
Gamaletous MN., Hayes G., Harris C., Brock J., Muldoon EG.,
Denning DW.
F508del CFTR gene mutation in patients with allergic bronchopulmonary aspergillosis
Journal of Asthma 2018; 55: 837 - 843
Guillón A., Brea D., Laceza E., Herve V., Hasanat S., Thorey C.,
Perez-Cruz M., Hordeaux J., Manikkanj J., Gosset P., Corea C.,
Si-Tahar M.
Inactivation of the interleukin-22 pathway in the airways of cystic
fibrosis patients
Cytokine 2019; 113: 470 - 474
Gomez C., Carsin A., Gouitua M., Reunau-Gaubert M., Dubus
JC., Mege Jl., Ranque S., Vitte J.
Mast cell tryptase changes with Aspergillus fumigatus - Host
cross-talk in cystic fibrosis patients
Journal of Cystic Fibrosis 2018; 17: 631 - 635
Kathriachchige G., Daley C., Pallin M., Polkinghorne K., King
PT.
C-reactive protein levels in acute respiratory exacerbations of cystic
fibrosis
Internal Medicine Journal 2018; 48: 1392 - 1395
Merakou C., Schaefers MM., Priebi GP.
Progress Toward the Elusive Pseudomonas aeruginosa Vaccine
Surgical Infections 2018; 35: 499 - 507
Montgomery ST., Dittrich AS., Garratt I.W., Turkovic L., Frey
DL., Stick SM., Mall MA., Kiece A.
Interleukin-1 is associated with inflammation and structural lung
disease in young children with cystic fibrosis
Journal of Cystic Fibrosis 2018; 17: 713 - 722
Philippe R., Urbauch V.
Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis
International Journal of Molecular Sciences 2018; 19: 10:2865
Rimessi A., Bezzarri V., Salvatori F., Tamanini A., Nigro F.,
Dechechi MC., Santangelo A., Prandini P., Munari S., Proveza
L., de Loubresse NG., Muller J., Ribeiro CMP., Lippi G.,
Gambari R., Pinton P., Cabrini G.,
PLCB3 Loss of Function Reduces Pseudomonas aeruginosa-a-
Dependent IL-8 Release in Cystic Fibrosis
American Journal of Respiratory Cell and Molecular Biology 2018;
59: 428 - 436
Robledo-Aviha FL., Ruiz-Rosado JD., Brockman KL., Kopp BT.,
Amer AO., McCoy K., Bakalez L.O., Parida-Sanchez S.
Disregulated Calcium Homeostasis in Cystic Fibrosis Neutrophils
Leads to Deficient Antimicrobial Responses
Journal of Immunology 2018; 201: 2016 - 2027
Roesch EA., Nichols DP., Chmil JF.
Inflammation in cystic fibrosis: An update
Pediatric Pulmonology 2018; 53:
Velard F., Jourdian ML., Abdallah D., Jacquot J., Ronan N.,
McCarthy Y., Flanagan E., Plant B.
Overexpression of RANK and M-CSFR in Monocytes of G551D-
Bearing Patients with Cystic Fibrosis
American Journal of Respiratory and Critical Care Medicine 2018;
198: 968 - 970
Wagner CE., Wheeler KM., Ribbeck K.
Mucins and Their Role in Shaping the Functions of Mucus Barriers
Annual Review of Cell and Developmental Biology, Vol 34 2018; 34:
189 - 215
Liver Disease


Davison S. Assessment of liver disease in cystic fibrosis. Paediatric Respiratory Reviews 2018; 27: 24 - 27

Klymenko VA, Piontkovska OV, Pasichnyk OV, Drobova NM, Yanovska KO, Bevz SL, Sindicieva NT. A clinical case report of cystic fibrosis and liver cirrhosis in a child. Zaporozhye Medical Journal 2018; : 739 - 742

Nascimento FD, Sena NA, Ferreira TD, Marques CDF, Silva LR, Souza EL. Hepatobiliary disease in children and adolescents with cystic fibrosis. Jornal de Pediatria 2018; 94: 504 - 510

Polineni D, Piccorelli AV, Hannah WB, Dalrymple SN, Pace RG, Durie PR, Ling SC, Knowles MR, Stonebraker JR. Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population. PLoS One 2018; 13: 10.e0205257


Microbiology


Akl N, Muhlebach MS. Biology and management of methicillin resistant Staphylococcus aureus in cystic fibrosis. Pediatric Pulmonology 2018; 53:


Alkhanzi Z, Salouiti M, Ardestani MS. Synthesis and immunological evaluation of a nanovaccine based on PLGA nanoparticles and algin ate antigen against infections caused by Pseudomonas aeruginosa. Biomedical Physics & Engineering Express 2018; 4: 4:UNSP 045016


Bara JJ, Matson Z, Remold SK. Life in the cystic fibrosis upper respiratory tract influences competitive ability of the opportunistic pathogen Pseudomonas aeruginosa. Royal Society Open Science 2018; 5: 9:180623


Cacador NC, Capizzano CPD, Torres LAGMM, Galetti R, Ciofu O, Darini ALD, Flefiby N. Adaptation of Pseudomonas aeruginosa to the chronic phenotype by mutations in the algTmucABD operon in isolates from Brazilian cystic fibrosis patients. PLoS One 2018; 13: 11.e0208013


De Baets F, De Keyzer L, Van Daele S, Schelstraete P, Van Biervliet S, Van Braeckel E, Thomas M, Wanyama SS. Risk factors and impact of allergic bronchopulmonary aspergillosis in Pseudomonas aeruginosa-negative CF patients. Pediatric Allergy and Immunology 2018; 29: 726 - 731
Dennis EA., Coats MT., Griffin S., Pang B., Briles DE., Crain MJ., Swords WE.
Hypercapsulated mucoid pneumococcal isolates from patients with cystic fibrosis have increased biofilm density and persistence in vivo
Pathogens and Disease 2018; 76: 7:fy073

Dobay O., Laub K., Sterez B., Keri A., Balazs B., Tothpal A., Kardos S., Jaikumpun P., Rukuksi K., Quinton PM., Zsembery A.
Bicarbonate Inhibits Bacterial Growth and Biofilm Formation of Prevalent Cystic Fibrosis Pathogens
Frontiers in Microbiology 2018; 9: ArNo: 2245

Dupont C., Jumas-Bilak E., Doisy C., Aujoulat F., Chiron R., Marchandin H.
Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment
Applied and Environmental Microbiology 2018; 84: 23:UNSP e01739

Eckstrom K., Willsley GG., LiPuma JJ., Wargo MJ.
Draft Genome Sequences of Two Cystic Fibrosis Strains of Stenotrophomonas maltophilia, AU30115 and AU32848
Microbiology Resource Announcements 2018; 7: 11:UNSP e01137

Eye S., Pierard D., De Wachter E., Eckhout L., Vaes P., Malfroot A.
Respiratory Bacterial Culture Sampling in Expectorating and Non-expectorating Patients With Cystic Fibrosis
Frontiers in Pediatrics 2018; 6: ArNo: 403

Faure E., Kwong K., Nguyen D.
Pseudomonas aeruginosa in Chronic Lung Infections: How to Adapt Within the Host?
Frontiers in Immunology 2018; 9: ArNo: 2416

Gomes MC., Tasrini Y., Subramoni S., Agnoli K., Feliciano JR., Eberl L., Sokol P., O’Callaghan D., Vergnacus AC.
The afc anfungal activity cluster, which is under tight regulatory control of ShvR, is essential for transition from intracellular persistence of Burkholderia cenocepacia to acute pro-inflammatory infection.
PloS Pathogens 2018; 14: 12:e1007473

Gramegna A., Millar BC., Blasi F., Elborn JS., Downey DG., Moore JE.
In vitro antimicrobial activity of cefotizole/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis
Journal of Global Antimicrobial Resistance 2018; 14: 224 - 227

Green H., Jones AM.
Emerging Gram-negative bacteria: pathogenic or innocent bystanders
Current Opinion in Pulmonary Medicine 2018; 24: 592 - 598

Gungor O., Sampaio-Maia B., Amorim A., Araujo R., Erturan Z.
Detection of Azole Resistance and TR34/L98H Mutations in Isolates of Aspergillus Section Fumigati from Turkish Cystic Fibrosis Patients
Mycopathologia 2018; 183: 913 - 920

Hahn A., Burrell A., Fanous H., Chaney H., Sami L., Perez GF., Koumbourlis AC., Freishtat RJ., Crandall KA.
Antibiotic multidrug resistance in the cystic fibrosis airway microbiome is associated with decreased diversity
Heliyon 2018; 4: 9:UNSP e00795

Heriot M., Nottelet B., Garric X., D’Este M., Richards GR., Moriarty FT., Eglin D., Guillaume O.
Interaction of geltanacin sulfonate with alginates and consequences on the physico-chemical properties of alginate-containing biofilms
International Journal of Biological Macromolecules 2019; 121: 390 - 397

Hong G., Poser KJ., Jennings MT., Merlo CA., Boyle MP., Hadjiliadis D., Kwauk SM., Lechtzin N.
Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis
Journal of Cystic Fibrosis 2018; 17: 624 - 630

Hoo ZH., Coates E., Maguire C., Cantrill H., Shafi N., Nash EF., McGowan A., Bourke SJ., Flight WG., Daniels TV., Nightingale JA., Allenby ML., Curley R., Wildman MJ.
Pragmatic criteria to define chronic pseudomonas aeruginosa infection among adults with cystic fibrosis
European Journal of Clinical Microbiology & Infectious Diseases 2018; 37: 2219 - 2222

BpeB, a major resistance-nodulation-cell division transporter from Burkholderia cenocepacia: construct design, crystallization and preliminary structural analysis
Acta Crystallographica Section F structural Biology Communications 2018; 74: 710 - 716

Hoyle N., Zhvanitsya P., Balarajshvili N., Bolkvadze D., Nadareishvili L., Nizhzaradze D., Wittmann J., Rohde C., Kutateladze M.
Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report
Research in Microbiology 2018; 169: 540 - 542

Huang Q., Wang YQ., Xia Y., Li I.W., Luo J., Xia SX., Sun Y., Miao YL., Wang KH., Chen Y.
Testing the neutral theory of biodiversity with the microbiome dataset from cystic fibrosis patients
Medicine 2018; 97: 37:e12248

Hurley MN., Smyth AR.
Staphylococcus aureus in cystic fibrosis: pivotal role or bit part actor?
Current Opinion in Pulmonary Medicine 2018; 24: 586 - 591

Establishing the diagnosis of chronic colonization with Pseudomonas aeruginosa of cystic fibosis patients: Comparison of the European consensus criteria with genotyping of P-aeruginosa isolates
Journal of Cystic Fibrosis 2018; 17: 729 - 735

Kevat A., Carzino R., Massie J., Harrison J., Griffiths AL.
Elimination of Australian epidemic strain (AES1) pseudomonas aeruginosa in a pediatric cystic fibrosis center
Pediatric Pulmonology 2018; 53: 1498 - 1503

Kiedrowski MR., Bomberger JM.
Viral-Bacterial Co-infections in the Cystic Fibrosis Respiratory Tract
Frontiers in Immunology 2018; 9: ArNo: 3067

Kirienko DR., Kang D., Kirienko NV.
Novel Pyoverdine Inhibitors Mitigate Pseudomonas aeruginosa Pathogenesis
Frontiers in Microbiology 2019; 9: ArNo: 3317

Lotfy WA., Atallah RG., Sabra WA., El-Helow ER.
Expression of extracellular polysaccharides and proteins by clinical isolates of Pseudomonas aeruginosa in response to environmental conditions
International Microbiology 2018; 21: 129 - 142

Lozano C., Azcona-Gutierrez JM., Van Bambeke F., Saenz Y.
Great phenotypic and genetic variation among successive chronic Pseudomonas aeruginosa from a cystic fibrosis patient

Mangiaterra G., Amirì M., Di Cesare A., Passaruolì S., Manso E., Cirilli N., Citterio B., Vignaroli C., Biavasco F.
Detection of viable but non-culturable Pseudomonas aeruginosa in cystic fibrosis by qPCR: a validation study
BMC Infectious Diseases 2018; 18: ArNo: 701

Martin I.W., Robson CL., Watts AM., Gray AR., Wainwright CE., Bell SC., Ramsay KA., Kidd TJ., Reid DW., Brockway B., Lamont IL.
Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients
Antimicrobial Agents and Chemotherapy 2018; 62: 11.e01789-18

Martiniano SL., Nick JA., Daley CL.
Nontuberculous Mycobacterial Infections in Cystic Fibrosis
International Journal of Molecular Sciences 2018; 19: 12:3759

Pita T., Feliciano JR., Leitao JH.
Small Noncoding Regulatory RNAs from Pseudomonas aeruginosa
Journal of Bacteriology 2018; 200: 22:e00428

Perault AI., Cotter PA.
Three Distinct Contact-Dependent Growth Inhibition Systems Mediate Intercellular Competition by the Cystic Fibrosis Pathogen Burkholderia dolosa
Journal of Bacteriology 2018; 200: 22:e00428-18

Pita T., Feliciano JR., Leiao LH.
Small Noncoding Regulatory RNAs from Pseudomonas aeruginosa and Burkholderia cepacia Complex
International Journal of Molecular Sciences 2018; 19: 12:3759

In vitro activity of N-acetylcycteine against Stenotrophomonas maltophilia and Burkholderia cepacia complex grown in planktonic phase and biofilm

Pompilio A., Geminiani C., Mantini P., Siriwardena TN., Di Bonaventura L., Raymont JL., Di Bonaventura G.
Peptide dendrimers as "lead compounds" for the treatment of chronic lung infections by Pseudomonas aeruginosa in cystic fibrosis patients: in vitro and in vivo studies
Infection and Drug Resistance 2018; 11: 1767 - 1782

Poudyal B., Sauer K.
The PA3177 Gene Encodes an Active Diguanylate Cyclase That Contributes to Biofilm Antimicrobial Tolerance but Not Biofilm Formation by Pseudomonas aeruginosa
Antimicrobial Agents and Chemotherapy 2018; 62: 10.e01049-18

Powell LC., Pritchard MF., Ferguson EL., Powell KA., Patel SU., Rye PD., Sakellakou SM., Buurma NJ., Brillant CD., Copping JM., Menzies GE., Lewis PD., Hill KE., Thomas DW.
Targeted disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginic oligosaccharides
NPJ Biofilms and Microbiomes 2018; 4: ArNo: UNSP 13

Ravnholt C., Kolpen M., Skov M., Moser C., Katzenstein TL., Plessor T., Holby N., Qvist T.
The importance of early diagnosis of Mycobacterium abscessus complex in patients with cystic fibrosis
APMIS 2018; 126: 885 - 891

Redero M., Lopez-Causape C., Aznar J., Oliver A., Blazquez J., Prieto AI.
Susceptibility to R-pyocins of Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients
Journal of Antimicrobial Chemotherapy 2018; 73: 2770 - 2776

Emergence and Within-Host Genetic Evolution of Methicillin-Resistant Staphylococcus aureus Resistant to Linezolid in a Cystic Fibrosis Patient
Antimicrobial Agents and Chemotherapy 2018; 62: 12.e00720-18

Schick A., Kassen R.
Rapid diversification of Pseudomonas aeruginosa in cystic fibrosis lung-like conditions
Proceedings of the National Academy of Sciences of the United States of 2018; 115: 10714 - 10719

Staphylococcus aureus in the airways of cystic fibrosis patients - A retrospective long-term study
International Journal of Medical Microbiology 2018; 308: 631 - 639

Secor PR., Michaels LA., Ratjen A., Jennings JK., Singh PK.
Entropically driven aggregation of bacteria by host polymers promotes antibiotic tolerance in Pseudomonas aeruginosa
Proceedings of the National Academy of Sciences of the United States 2018; 115: 10780 - 10785

Song Y., Keatley LR., Middleton PG.
Methicillin-resistant Staphylococcus aureus in health-care workers with cystic fibrosis in Sydney
Respirology Case Reports 2018; 6: 9.e00338

Stockwell RE., Wood ME., He C., Sherrard LJ., Ballard EL., Kidd TJ., Johnson GR., Knibbs LD., Morawska L., Bell SC.
Face Masks Reduce the Release of Pseudomonas aeruginosa Cough Aerosols When Worn for Clinically Relevant Periods
American Journal of Respiratory and Critical Care Medicine 2018; 198: 1339 - 1342

Subedi D., Vijay AK., Kohli GS., Rice SA., Willcox M.
Association between possession of ExoU and antibiotic resistance in Pseudomonas aeruginosa

Tetz G., Tetz V.
Draft Genome Sequence of Chryseobacterium mucoviscidosis sp. nov. Strain VT16-26, isolated from the Bronchoalveolar Lavage Fluid of a Patient with Cystic Fibrosis
Microbiology Resource Announcements 2018; 6: 2:UNSP e01473

Tracy MC., Moss RB.
The myriad challenges of respiratory fungal infection in cystic fibrosis
Pediatric Pulmonology 2018; 53: 1078-1085

Trend S., Chang BJ., O’Dea M., Stiek SM., Kicic A.
Use of a Primary Epithelial Cell Screening Tool to Investigate Phage Therapy in Cystic Fibrosis
Frontiers in Pharmacology 2018; 9: ArNo: 1330

Varies Greatly during Infections in Cystic Fibrosis Patients
Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes
Antimicrobial Agents and Chemotherapy 2018; 62: 11.e01789-18

Arnaud C., Garnier F., Leraut J., Lepainteur M., Rahajamananana L., Languelin J., Ploy MC., Bourgeois-Nicolaos N., Doucet-Populaire F.
Emergence and Within-Host Genetic Evolution of Methicillin-Resistant Staphylococcus aureus Resistant to Linezolid in a Cystic Fibrosis Patient
Antimicrobial Agents and Chemotherapy 2018; 62: 12.e00720-18

Schick A., Kassen R.
Rapid diversification of Pseudomonas aeruginosa in cystic fibrosis lung-like conditions
Proceedings of the National Academy of Sciences of the United States of 2018; 115: 10714 - 10719

Staphylococcus aureus in the airways of cystic fibrosis patients - A retrospective long-term study
International Journal of Medical Microbiology 2018; 308: 631 - 639

Secor PR., Michaels LA., Ratjen A., Jennings JK., Singh PK.
Entropically driven aggregation of bacteria by host polymers promotes antibiotic tolerance in Pseudomonas aeruginosa
Proceedings of the National Academy of Sciences of the United States 2018; 115: 10780 - 10785

Song Y., Keatley LR., Middleton PG.
Methicillin-resistant Staphylococcus aureus in health-care workers with cystic fibrosis in Sydney
Respirology Case Reports 2018; 6: 9.e00338

Stockwell RE., Wood ME., He C., Sherrard LJ., Ballard EL., Kidd TJ., Johnson GR., Knibbs LD., Morawska L., Bell SC.
Face Masks Reduce the Release of Pseudomonas aeruginosa Cough Aerosols When Worn for Clinically Relevant Periods
American Journal of Respiratory and Critical Care Medicine 2018; 198: 1339 - 1342

Subedi D., Vijay AK., Kohli GS., Rice SA., Willcox M.
Association between possession of ExoU and antibiotic resistance in Pseudomonas aeruginosa

Tetz G., Tetz V.
Draft Genome Sequence of Chryseobacterium mucoviscidosis sp. nov. Strain VT16-26, isolated from the Bronchoalveolar Lavage Fluid of a Patient with Cystic Fibrosis
Microbiology Resource Announcements 2018; 6: 2:UNSP e01473

Tracy MC., Moss RB.
The myriad challenges of respiratory fungal infection in cystic fibrosis
Pediatric Pulmonology 2018; 53: 1078-1085

Trend S., Chang BJ., O’Dea M., Stiek SM., Kicic A.
Use of a Primary Epithelial Cell Screening Tool to Investigate Phage Therapy in Cystic Fibrosis
Frontiers in Pharmacology 2018; 9: ArNo: 1330
van der Bruggen T., Kolecka A., Theelen B., Kwakkel-ten-Verp JM., Arets B., Boekhout T.
Cutaneotrichosporon (Cryptococcus) cyanovorans, a basidiomycetous yeast, isolated from the airways of cystic fibrosis patients
Medical Mycology Case Reports 2018; 22: 18 - 20

Gut microbiota signatures in cystic fibrosis: Loss of host CFTR function drives the microbiota enterotype
PLoS One 2018; 13: e0208171

Vinokurova I.V., Baimakanova GE., Krasovsky SA., Silvestrova SY., Dubeitsova E.A., Yarvanina GG., Bordlin DS.
Functional insufficiency of the pancreas and the metabolic activity of the microbiota in cystic fibrosis adults
Terapreveticheskii Arkhiv 2018; 90: 84 - 88

Vongthlath R., Thiriez BR., Dehillotte C., Lemonnier L., Guillien A., Degano B., Dalphin ML., Dalphin JC., Pleisat P.
Clinical and microbiological characteristics of cystic fibrosis adults never colonized by Pseudomonas aeruginosa: Analysis of the French CF registry
PLoS One 2019; 14: 1:e0210201

Wang J., Li Y., Yan HZ., Luo XH., Feng XQ., Lu LF., Wang WJ.
Association between the Pseudomonas aeruginosa type III secretion system, antibiotic resistance and clinical features
International Journal of Clinical and Experimental Medicine 2018; 1: 11120 - 11126

Wood ME., Stockwell RE., Johnson GR., Ramsay KA., Sherrard LJ., Kidd TJ., Cheney J., Ballard EL., O’Rourke P., Jabbour N., Wainwright CE., Knibbs LD., Syl PD., Morawska L., Bell SC.
Cystic fibrosis pathogens survive for extended periods within cough-generated droplet nuclei
Thorax 2019; 74: 87 - 90

Woods PW., Haynes ZM., Mina EG., Marques CNH.
Maintenance of S. aureus in co-culture with P. aeruginosa while growing as Biofilms
Frontiers in Microbiology 2019; 9: ArNo: 3291

Yu ZJ., Deslouches B., Walton WG., Redinho MR., Di YP.
Enhanced biofilm prevention activity of a SPLUNC1 antimicrobial peptide against Staphylococcus aureus
Clinical Microbiology Reviews 2018; 31: 4:UNSP e00019

Zhao JM., Yu WC.
Relationship of Initial Pancreatic Enzyme Replacement Therapy Dose With Weight Gain in Infants With Cystic Fibrosis
Journal of Pediatric Gastroenterology and Nutrition 2018; 67: 520 - 526

Physiotherapy
Ghasempour M., Bilan N., Rezzadethsaaflou M.
Positive Expiratory Pressure (PEP) versus Conventional Chest Physiotherapy in Pediatric Patients with Acute Exacerbation of Cystic Fibrosis

Psychosocial
Work environment risks for health care workers with cystic fibrosis
Respirology 2018; 23: 1190 - 1197


Gancz DW, Cunha MT, Leone C, Rodrigues JC, Adde FV. Quality of life amongst adolescents and young adults with cystic fibrosis: correlations with clinical outcomes. Clinics 2018; 73: ArNo: UNSP e42

Gomes A, Rothpletz-Puglia P, Matarese L, Ziegler J. The Impact of Weight Status on Health-Related Quality of Life and Body Image in Adults With Cystic Fibrosis A Narrative Review Topics in Clinical Nutrition 2018; 33: 164 - 178


Lapp V, Chase SK. How Do Youth with Cystic Fibrosis Perceive Their Readiness to Transition to Adult Healthcare Compared to Their Caregivers’ Views? Journal of Pediatric Nursing-nursing Care of Children & Families 2018; 43: 104 - 110


Mather EF, Polineni D, Sawicki GS. Overcoming psychosocial challenges in cystic fibrosis: Promoting resilience. Pediatric Pulmonology 2018; 53:


Oud L, Chan YM. Predictors and variation of routine home discharge in critically ill adults with cystic fibrosis. Heart & Lung 2018; 47: 511 - 515


### Pulmonology


Bruga R, Edmondson C, Davies JC. Outdoor air pollution and cystic fibrosis. Paediatric Respiratory Reviews 2018; 28: 80 - 86


Eiserich JP, Ott SP, Kadir T, Morrissey BM, Hayakawa KA, La Merrill MA, Cross CE. Quantitative assessment of cyanide in cystic fibrosis sputum and its oxidative catabolism by hypochlorous acid. Free Radical Biology and Medicine 2018; 129: 146 - 154
Ermund A., Meiss LN., Dolan B., Bahar A., Klymiuk N., Hansson GC.
The mucus bundles responsible for airway cleaning are retained in
cystic fibrosis and by cholinergic stimulation
European Respiratory Journal 2018; 52: 2:1800457

Formo E., Abraham N., Winger DG., Rosas-Salazar C., Kurland G., Weiner DJ.
Perception of Pulmonary Function in Children with Asthma and
Cystic Fibrosis
Pediatric Allergy Immunology and Pulmonology 2018; 31: 139 - 145

Gallant JN., Mitchell MB., Virgin FW.
Update on sinus disease in children with cystic fibrosis: advances in
treatment modalities, microbiology, and health-related quality-of-life
instruments
Current Opinion in Otolaryngology & Head and Neck Surgery 2018;
26: 417 - 420

Hill DB., Long RF., Kissner WJ., Atieh E., Garbarine IC.,
Markovetz MR., Fontana NC., Christy M., Habibpou M.,
Tarran R., Forest MG., Boucher RC., Button B.
Pathological mucus and impaired mucus clearance in cystic fibrosis
patients result from increased concentration, not altered pH
European Respiratory Journal 2018; 52: 6:1801297

Lafoeste H., Regard L., Martin C., Chassagnon G., Burgel PR.
Acute pulmonary and non-pulmonary complications in adults with
cystic fibrosis
Revue de Pneumologie Clinique 2018; 74: 267 - 278

Magalhaes M., Tost J., Pinea F., Rivals I., Busato F., Alary N.,
Mely L., Lery S., Murriz M., Caimin D., Claustres M., Chiron R., De Sario A.
Dynamic changes of DNA methylation and lung disease in cystic
fibrosis: lessons from a monogenic disease
Epigenomics 2018; 10: 1131 - 1145

Massip-Copiz MM., Santa-Coloma TA.
Extracellular pH and lung infections in cystic fibrosis
European Journal of Cell Biology 2018; 97: 402 - 410

Mendelsohn L., Wijers C., Gupta R., Marozkina N., Li C., Gaston B.
A novel, noninvasive assay shows that distal airway oxygen tension is
low in cystic fibrosis, but not in primary ciliary dyskinasia
Pediatric Pulmonology 2019; 54: 27 - 32

Nolt VD., Piujt KD., Autry EB., Williams WC., Burgess DS.,
Burgess DR., Arora V., Kuhn RJ.
Amikacin target achievement in adult cystic fibrosis patients utilizing
Monte Carlo simulation
Pediatric Pulmonology 2019; 54: 33 - 39

Perrem L., Raynent JH., Ratjen F.
The lung clearance area as a monitoring tool in cystic fibrosis: ready
for the clinic?
Current Opinion in Pulmonary Medicine 2018; 24: 579 - 585

Radine A., Werner C., Raidt J., Dougherty GW., Kerschke L.,
Omar H., Grosse-Onnebrink J.
Comparison of Nocturnal Cough Analysis in Healthy Subjects and
in Patients with Cystic Fibrosis and Primary Ciliary Dyskinesia: A
Prospective Observational Study
Respiration 2019; 97: 60 - 69

Regard L., Martin C., Chassagnon G., Burgel PR.
Acute and chronic non-pulmonary complications in adults with
cystic fibrosis

Roethlisberger K., Nyias S., Riedel T., Wolfensberger J., Singer F.,
Latzin P.
Short-Term Effects of Elastic Chest Wall Restriction on Pulmonary
Function in Children with Cystic Fibrosis
Respiration 2018; 96: 535 - 542

Schechter MS., Schmidt HJ., Williams R., Norton R., Taylor D.,
Molzho D.
Impact of a program ensuring consistent response to acute drops in
lung function in children with cystic fibrosis
Journal of Cystic Fibrosis 2018; 17: 769 - 778

Szentpetery S., Flume PA.
Optimizing outcomes of pulmonary exacerbations in cystic fibrosis
Current Opinion in Pulmonary Medicine 2018; 24: 606 - 611

Tomlinson OW., Barker AR., Chuchook LV., Stevens D., Saynor ZL.,
Oades PJ., Williams CA.
Analysis of oxygen uptake efficiency parameters in young people
with cystic fibrosis
European Journal of Applied Physiology 2018; 118: 2055 - 2063

Vendruscolo FM., Heinmann JP., da Silva JS., Ruiz MP.,
Donadio MVF.
Peak Oxygen Uptake and Mortality in Cystic Fibrosis: Systematic
Review and Meta-Analysis
Respiratory Care 2019; 64: 91 - 98

Webster MJ., Reidel B., Tan CD., Ghosh A., Alexis NE.,
Donaldson SH., Kesimer M., Ribeiro CMP., Tarran R.
SPLUNC1 degradation by the cystic fibrosis mucosal environment
drives airway surface liquid dehydration
European Respiratory Journal 2018; 52: 4:1800668

[Anonymous].
Reevaluating approaches to cystic fibrosis pulmonary exacerbations
Pediatric Pulmonology 2018; 53:

[Anonymous].
Retraction: Phenazine Content in the Cystic Fibrosis Respiratory
Tract Negatively Correlates with Lung Function and Microbial
Complexity
American Journal of Respiratory Cell and Molecular Biology 2019;
60: 134

Radiology

Chassagnon G., Martin C., Burgel PR., Hubert D., Fajac L.,
Paragios N., Zacharakis EJ., Legmann P., Coste J., Revel MP.
An automated computed tomography score for the cystic fibrosis lung
European Radiology 2018; 28: 5111 - 5120

Hill DB., Long RF., Kissner WJ., Atieh E., Garbarine IC.,
Markovetz MR., Fontana NC., Christy M., Habibpou M.,
Tarran R., Forest MG., Boucher RC., Button B.
Pathological mucus and impaired mucus clearance in cystic fibrosis
patients result from increased concentration, not altered pH
European Respiratory Journal 2018; 52: 6:1801297

Manzini M., Schweiger C., Manica D., Machado I.R., Lopes
PDD., Skenie L., Facin CS., BejmanPilcher O.,
CauduroMarostica PJ.
Sinonasal computed tomography in pediatric cystic fibrosis: do we
know the indications?
International Journal of Pediatric Otorhinolaryngology 2018; 113: 204 - 207

Nandurkar R., Lau KK.
Ultra-low-dose Computed Tomography in Management of Pulmonary
Abscess Caused by Cystic Fibrosis
Hong Kong Journal of Radiology 2018; 21: 271 - 273

Naseri Z., Shirafat S., Moghadam H.A., Modaresi M., Pak N.,
Zamani F.
Semi-automatic Methods for Airway and Adjacent Vessel
Measurement in Bronchiectasis Patterns in Lung HRCT Images of
Cystic Fibrosis Patients
Journal of Digital Imaging 2018; 31: 727 - 737

Newbeggin K., Pilkington K., Shanthikumar S., Ranganathan S.
Clinical utility of surveillance computed tomography scans in infants
with cystic fibrosis
Pediatric Pulmonology 2018; 53: 1387 - 1390

Poepper-Lang S., Stauffer K., Bultz P., Tamandl D., Muin D.,
Bastani N., Hallibasic E., Hodg JC., Trauner M., Kazemi-Shirazi
L., Ba-Salamah A.
The Efficacy of MRI in the diagnostic workup of cystic fibrosis-
associated liver disease: A clinical observational cohort study
European Radiology 2019; 29: 1048 - 1058


**Screening**


**Therapy (Non Antimicrobial)**


Anderson SD., Daviskas E., Brannan JD., Chan HK. Repurposing excipients as active inhalation agents: The mannitol story. *Advanced Drug Delivery Reviews* 2018; 133: 45 - 56.


Labonte ML.
The Mist Tent: An Analysis of Therapeutic Change in the History of Cystic Fibrosis Care
*Journal of the History of Medicine* 2018; 92: 634 - 663

Maitri L., Kroemer G.
Autophagy delays progression of the two most frequent human monogenic lethal diseases: cystic fibrosis and Wilson disease
*Aging-as* 2018: 10: 3657 - 3661

McElvaney OJ, Gunaratnam C., McElvaney OF., Bagwe L., Reeves EP., McElvaney NG.
Emerging pharmacotherapies in cystic fibrosis

Miliar BC., Rendall JC., Downey DG., Moore JE.
Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against *Pseudomonas aeruginosa?* Results of an in vitro study
*Journal of Clinical Pharmacy and Therapeutics* 2018; 43: 836 - 843

Mitchell RM., Jones AM., Barry PJ.
CFTR modulator therapy in patients with cystic fibrosis and an organ transplant
*Paediatric Respiratory Reviews* 2018; 27: 6 - 8

Ooi CY., Syed SA., Rossi L., Garg M., Needham B., Avolio J., Young K., Surette MG., Gonska T.
Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation
*Scientific Reports* 2018; 8: ArNo: 17834

Phuah PW., Son JH., Tan JA., Li C., Musante L., Zlock L., Nielson DW., Finkbeiner WE., Kurth MJ., Galletta LJ., Haggie PM., Verkanm AS.
Combination potentiator ('co-potentiatior') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators
*Journal of Cystic Fibrosis* 2018; 17: 595 - 606

Pohl K., Nichols DP., Taylor-Cousar JL., Saavedra MT., Strand MJ., Nick JA., Bratcher PE.
Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation

Pollard BS., Pollard HB.
Induced pluripotent stem cells for treating cystic fibrosis: State of the science
*Pediatric Pulmonology* 2018; 53:

Rodriguez-Miguez P., Lee N., Tucker MA., Csanay G., McKie KT., Forseen C., Harris RA.
Sildenafil improves vascular endothelial function in patients with cystic fibrosis
*American Journal of Physiology-heart and Circulatory Physiology* 2018; 315: H1486 - H1494

Sawicki GS., Fink AK., Schechter MS., Loefller DR., Mayer-Hamblett N.
Rate and predictors of prescription of lumacaftor - Ivacaftor in the 18 months following approval in the United States
*Journal of Cystic Fibrosis* 2018; 17: 742 - 746

Sharma D., Xing S., Hung YT., Caskey RN., Dowell ML., Touchette DR.
Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States
*Orphanet Journal of Rare Diseases* 2018; 13: ArNo: 172

Southern KW., Patel S., Sinha JP., Nevitt SJ.
Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
*Cochrane Database of Systematic Reviews* 2018; : 8:CD010966

Stallings VA., Sainath N., Oberle M., Bertolaso C., Schall JI.
Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations
*Journal of Pediatrics* 2018; 201: 229 - +

Trimble A., McKinzie C., Terrell M., Stringer E., Esther CR.
Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding
*Journal of Cystic Fibrosis* 2018; 17: 779 - 782

Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis
*Journal of Cystic Fibrosis* 2018; 17: 650 - 656

Vadagam P., Kamal KM., Covyee JR., Giannetti V., Mukherjee K.
Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis
*Journal of Managed Care & Specialty Pharmacy* 2018; 24: 987 - +

Wang YT., Cai ZW., Gosling M., Sheppard DN.
Potentiation of the cystic fibrosis transmembrane conductance regulator Cl- channel by ivacaftor is temperature independent

Wark P., McDonald VM.
Nebulised hypertonic saline for cystic fibrosis
*Cochrane Database of Systematic Reviews* 2018; : 9:CD001506

Yang CN., Montgomery M.
Dornase alpha for cystic fibrosis
*Cochrane Database of Systematic Reviews* 2018; : 9:CD001127

[Anonymous].
Tezacaftor/Ivacaftor (Symdeko) for Cystic Fibrosis
*Medical Letter On Drugs and Therapeutics* 2018; 60: 174 - 176

Transplantation

Ahmad O., Shafii AE., Mannino DM., Choute R., Baz MA.
Impact of donor lung pathogenic bacteria on patient outcomes in the immediate posttransplant period
*Transplant Infectious Disease* 2018; 20: 6:e12986

Leuhi F., Mullane D., Bugguy D., Flood G., Griffin M.
Anesthesia for Lung Transplantation in Cystic Fibrosis: Prospective Review from the Irish National Transplantation Centre
*Journal of Cardiothoracic and Vascular Anesthesia* 2018; 32: 2372 - 2380

Li SS., Tumin K., Krone KA., Boyer D., Kirkby SE., Mansour HM., Hayes D.
Risks associated with lung transplantation in cystic fibrosis patients

Miorachi LC., Greer M., Tudorache I., Blasi F., Welte T., Haverich A., Mainz JG., Gottlieb J.
The burden of sinus disease in cystic fibrosis lung transplant recipients
*Transplant Infectious Disease* 2018; 20: 6:e12944

Ouycarugulem C., Williams L., Zhu HR., Gazzanese MC., Melicoff E., Das S., Coss-Bu J., Lam F., Mallory G., Munoz FM.
Risk factors for infection after pediatric lung transplantation
*Transplant Infectious Disease* 2018; 20: 6:e13000

Savi D., Mordenti M., Bonci E., Troiani P., Giordani B., D’Alu V., Bertasi S., Cimino G., Rossi P., Poggi C., Palange P., Quattrucci S.
Survival After Lung Transplant for Cystic Fibrosis in Italy: A Single Center Experience With 20 Years of Follow-up
*Transplantation Proceedings* 2018; 50: 3732 - 3738

Skogeland U., de Monestrol I., Godskesen TE.
Experiences of Individuals Awaiting Lung Transplantation
*Respiratory Care* 2018; 63: 1535 - 1540

Waseda R., Benazzo A., Hoetzenecker K., Jakusch P., Murakozy G., Gruber S., Roth G., Szeplfalusi Z., Nachbaur E., Klepetko W.
The influence of retransplantation on survival for pediatric lung transplant recipients
*Journal of Thoracic and Cardiovascular Surgery* 2018; 156: 2025 - +